EDIT-101 is under clinical development by Editas Medicine and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect EDIT-101’s likelihood of approval (LoA) and phase transition for Leber Congenital Amaurosis (LCA) took place on 04 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their EDIT-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AGN-151587 is under development for the treatment of Leber congenital amaurosis 10. It is developed based on CRISPR/Cas9 and CRISPR/Cpf1 genome editing technology. It is administered through the subretinal route. The therapeutic candidate constitutes a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene-editing constructs. It is a new molecular entity. It acts by targeting CEP290.
Editas Medicine overview
Editas Medicine formerly Gengine, is a clinical stage biotechnology company focused on the development of genome treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palindromic repeats (CRISPR) technology. The company’s pre-clinical pipeline spans investigational candidates for the treatment of ocular and blood diseases, cancer, and diseases of other organs and tissues. The company works in collaboration with Allergan/ AbbVie Inc, AskBio, Bayer AG, BlueRock Therapeutics, The Broad Institute Inc, Massachusetts Institute of Technology, Harvard Institute, The Rockefeller University, Celgene Corp and Bristol Myers Squibb to discover and develop its pipeline products. Editas Medicine is headquartered in Cambridge, Massachusetts, the US.
Quick View EDIT-101 LOA Data
|Highest Development Stage|